Charming Medical Ltd (MCTA) — Institutional Holders, Q2 2026
3 institutional investment managers reported a MCTA position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $1.0M. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
MCTA in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
New positions
0
Added to
0
Trimmed
1
Sold out
0
Biggest buyers
None this quarter.
Biggest sellers
- UBS Group AGTrimmed · -700 sh-$20.5K
MCTA 13F holders ranked 1–3 of 3
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | UBS Group AG#1 · 24,249 sh | 24,249 | $711.8K | <0.01% | -2.8% |
| 2 | GEODE CAPITAL MANAGEMENT#2 · 10,752 sh | 10,752 | $315.6K | 0.00% | 0.0% |
| 3 | JFS WEALTH ADVISORS#3 · 5,850 sh | 5,850 | $0.00 | 0.00% | 0.0% |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.